By Budi Oetomo Narendra 
A significant breakthrough in oncology research, originating from the Dartmouth Cancer Center (DCC), reveals that telmisartan, a widely prescribed medication for high blood pressure, holds substantial promise in dramatically enhancing the effectiveness of olaparib, an important targeted therapy used in cancer treatment. This discovery not only broadens the potential applicability of olaparib to a larger patient population but also offers a novel strategy to overcome treatment resistance, a persistent challenge in cancer therapy. The groundbreaking findings, detailing how this FDA-approved drug can significantly boost the cancer-killing activity of olaparib, were recently published in The Journal for ImmunoTherapy of Cancer, sparking considerable optimism within the medical community.
Repurposing a Common Drug for a Complex Disease
The research underscores the profound potential of drug repurposing—identifying new therapeutic uses for existing, approved medications—particularly in the realm of oncology. Dr. Tyler J. Curiel, MD, MPH, FACP, senior and lead author of the study, emphasized the practical advantages of this approach: "This study shows that a common, safe, tolerable, convenient, and inexpensive drug may significantly improve how well an important class of cancer therapies works." The ability to leverage an established drug like telmisartan, with its well-understood safety profile and widespread availability, could significantly accelerate the development and implementation of more effective cancer treatments, bypassing years of costly and complex preclinical and clinical trials typically associated with novel drug development.
Understanding PARP Inhibitors and Their Limitations
Olaparib is a prominent member of a class of targeted cancer drugs known as PARP inhibitors (Poly ADP-ribose Polymerase inhibitors). These innovative medicines operate by exploiting specific vulnerabilities in cancer cells’ DNA repair mechanisms. Specifically, PARP inhibitors are most effective against tumors that exhibit defects in homologous recombination DNA damage repair (HRD), a critical pathway for repairing double-strand breaks in DNA. Such defects are commonly found in cancers associated with mutations in the BRCA1 and BRCA2 genes, which are well-known hereditary risk factors for breast, ovarian, prostate, and pancreatic cancers.
Since the initial FDA approval of olaparib in 2014 for advanced ovarian cancer, PARP inhibitors have revolutionized the treatment landscape for patients with BRCA-mutated cancers. They have demonstrated impressive efficacy in prolonging progression-free survival and, in some cases, overall survival, particularly in ovarian cancer, HER2-negative breast cancer, metastatic castration-resistant prostate cancer, and pancreatic adenocarcinoma. However, a significant limitation of PARP inhibitors lies in their specificity. Many cancers do not possess these particular DNA repair defects, rendering PARP inhibitors ineffective for a large segment of the patient population. Furthermore, even in patients who initially respond well to treatment, tumors often develop acquired resistance over time, leading to disease progression and recurrence. This intrinsic and acquired resistance represents a critical unmet medical need, driving intense research efforts to expand the utility of PARP inhibitors.
Telmisartan’s Dual Mechanism: Sensitizing Tumors and Activating Immunity
The Dartmouth team’s pivotal discovery is that telmisartan can effectively sensitize tumors to PARP inhibitors, crucially, even in the absence of the typical DNA repair weaknesses that these drugs usually depend on. This implies a potential to extend the benefits of PARP inhibitors to a much broader range of cancer patients who currently do not qualify for such treatments.
The preclinical experiments conducted by Dr. Curiel and his colleagues revealed a sophisticated, multi-faceted mechanism by which telmisartan exerts its cancer-enhancing effects. The combination of telmisartan with olaparib led to a significant increase in DNA damage within cancer cells. By exacerbating DNA damage, telmisartan likely overwhelms the remaining, albeit imperfect, DNA repair pathways in cancer cells, making them more vulnerable to the PARP inhibitor’s action.
Beyond directly increasing DNA damage, the treatment combination also ignited crucial immune defenses against the tumors. Specifically, it boosted the production of type I interferons. Type I interferons are powerful signaling molecules that play a central role in the innate immune response. They are critical for alerting the immune system to the presence of pathogens and abnormal cells, including cancer cells, thereby promoting their identification and attack. "This immune activation appears to be a key reason the combination works so well," Dr. Curiel noted, highlighting the synergy between direct cellular damage and the immune response.
A Unique Advantage Among Blood Pressure Medications
Telmisartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, a class widely prescribed for the management of hypertension, affecting millions globally. ARBs work by blocking the action of angiotensin II, a potent vasoconstrictor and a key component of the renin-angiotensin system (RAS), which regulates blood pressure and fluid balance. While other ARBs are also effective in lowering blood pressure, the Dartmouth researchers conducted comparative studies and found that telmisartan’s cancer-enhancing effects were remarkably unique within its class. This specificity suggests that telmisartan possesses distinct pharmacological properties or off-target effects beyond its primary role in blood pressure regulation, which contribute to its anti-cancer potential.
Adding another layer of therapeutic advantage, the study found that telmisartan also lowered levels of PD-L1 (Programmed Death-Ligand 1) inside tumor cells. PD-L1 is a protein that many cancer cells express on their surface as a mechanism to evade detection and destruction by the immune system. By binding to PD-1 receptors on immune cells (T-cells), PD-L1 effectively puts a "brake" on the immune response, allowing cancer cells to proliferate unchecked. The reduction of PD-L1 by telmisartan could thus render tumor cells more visible and susceptible to immune attack, potentially synergizing with existing immunotherapies, such as PD-1/PD-L1 checkpoint inhibitors, which have transformed the treatment of several advanced cancers.
Dr. Curiel elaborated on these multifaceted effects: "Telmisartan has several distinct anticancer effects that, together with targeted therapy, could make tumors more responsive to distinct types of treatments. We showed the improved efficacy with PARP inhibitors in this study, but we also have good data showing that telmisartan improves efficacy of distinct chemotherapy classes and immunotherapies in many other cancer types through related mechanisms." This statement hints at a broader therapeutic potential for telmisartan, extending beyond PARP inhibitors and possibly impacting a wider spectrum of cancers and treatment modalities.
Expedited Pathway to Clinical Application: Early Trials Underway
The established safety profile, oral administration, and general tolerability of telmisartan, even in individuals without hypertension, make it an ideal candidate for rapid translation from preclinical findings to clinical application in cancer patients. This drug repurposing strategy bypasses many of the hurdles and lengthy timelines associated with novel drug development. Recognizing this significant advantage, Dr. Curiel and his colleagues at DCC have already initiated two crucial clinical trials to evaluate the combination therapy in human patients.
One ongoing study is investigating the combination of telmisartan with olaparib in men diagnosed with metastatic, castration-resistant prostate cancer. Prostate cancer remains a significant health challenge, with metastatic castration-resistant forms representing an advanced stage of the disease that is particularly difficult to treat. Dr. Curiel reported an encouraging early sign: the first participant in this trial experienced an "exceptional response" to the treatment. While this is a single case and further data are needed, such early responses are critical for validating preclinical findings and fueling continued research.
A second trial has recently enrolled its first patient with platinum-resistant ovarian cancer. Ovarian cancer, often diagnosed at advanced stages, frequently develops resistance to platinum-based chemotherapy, a cornerstone of its treatment. The emergence of platinum resistance is a major clinical hurdle, leading to poor prognoses. If the telmisartan-olaparib combination can overcome this resistance, it would represent a profound therapeutic advance for these patients.
Broader Implications and Future Outlook
The findings from Dartmouth Cancer Center carry immense implications for the future of cancer treatment. If successful in larger clinical trials, the combination of telmisartan and olaparib could fundamentally alter the treatment paradigm for cancers currently targeted by PARP inhibitors. It could expand the pool of eligible patients, offering hope to those whose tumors lack the specific HRD mutations, and provide a new avenue to combat the notorious problem of acquired drug resistance.
From an economic perspective, the integration of an inexpensive, generic drug like telmisartan into cancer regimens could also lead to substantial cost savings in healthcare systems, making advanced cancer therapies more accessible globally. This aligns with a growing movement in oncology to find cost-effective solutions without compromising efficacy.
The immune activation observed with the telmisartan-olaparib combination further opens doors for synergistic approaches with immunotherapies. The reduction of PD-L1 expression, coupled with increased type I interferon production, suggests that telmisartan might act as an "immuno-sensitizer," potentially enhancing the efficacy of immune checkpoint inhibitors. Future research will undoubtedly explore these combinations, possibly leading to even more potent anti-cancer strategies.
Dr. Curiel expressed cautious optimism regarding the ongoing trials: "We are encouraged by what we are seeing so far. Our goal is to determine whether this combination approach can help more patients benefit from greater effectiveness of PARP inhibitors and other cancer treatment classes and potentially overcome resistance to these drugs." The journey from a preclinical discovery to a standard clinical practice is long and rigorous, but the initial data and the scientific rationale provide a robust foundation.
The research was made possible through crucial support from the Guyre fund and Gmelich fund at DCC, underscoring the vital role of philanthropic contributions in driving innovative cancer research and facilitating the rapid translation of scientific discoveries into potential patient benefits. As these early clinical trials progress, the medical and patient communities will eagerly await further results, hoping that this repurposed blood pressure drug will indeed unlock new frontiers in the fight against cancer.
